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Ironing out pyoverdine's chromophore structure: serendipity or design?  
Christine Cézard 1 • Pascal Sonnet 1,2 • Benjamin Bouvier *1 
Abstract Pyoverdines are Pseudomonas aeruginosa’s primary siderophores. These molecules, composed of a fluorescent chromophore attached to a peptide 
chain of 6 to 14 amino acids, are synthesized by the bacterium to scavenge iron (essential to its survival and growth) from its environment. Hijacking the 
siderophore pathway to use pyoverdine-antibiotic compounds in a Trojan horse approach has shown promise but remains very challenging because of the 
synthetic efforts involved. Indeed, both possible approaches (grafting an antibiotic on pyoverdine harvested from Pseudomonas or designing a total synthesis 
route) are costly, time-consuming and low-yield tasks. Designing comparatively simple analogs featuring the salient properties of the original siderophore is 
thus crucial for the conception of novel antibiotics to fight bacterial resistance. In this work, we focus on the replacement of the pyoverdine chromophore, a 
major roadblock on the synthetic pathway. We propose three simpler analogs and evaluate their ability to complex iron and interact with the FpvA transporter 
using molecular modeling techniques. Based on these results, we discuss the role of the native chromophore’s main features (polycyclicity, positive charge, 
flexibility) on pyoverdine’s ability to bind iron and be recognized by membrane transporter FpvA and propose guidelines for the design of effective synthetic 
siderophores. 
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Introduction 
Pseudomonas aeruginosa, a Gram-negative bacterium, is an 
opportunistic pathogen infecting humans with compromised 
immune defense causing chronic and/or life-threatening 
infections. It is the third most common Gram-negative 
pathogen causing bactaeremia and exhibits documented 
resistance to numerous antibiotics such as β-lactams, 
carbapenems, aminoglycosides, and fluoroquinolones.[1-3] The 
World Health Organization, which has recently elevated anti-
microbial resistance to crisis level[4], has placed P. aeruginosa 
on the top tier for priority. Developing novel strategies to 
overcome acquired resistance to antibiotics in P. aeruginosa 
and other such “superbugs” has thus become a global public 
health concern. The fact that a single new class of anti-infectives 
(oxazolidinones) has emerged on the market in the last two 
decades[5] is a good indicator of the criticality of the situation. 
Fortunately, academic and fundamental research focused on 
deciphering host-pathogen interactions is intensifying and 
some approaches show promising outcomes in the fight against 
superbugs.[6] Examples include (i) developing peptides to 
specifically inhibit bacterial biofilm formation,[7, 8] (ii) 
bypassing the low permeability of the bacterial outer 
membrane, (iii) inhibiting the active efflux system in charge of 
expelling small molecules such as antibiotics,[9-11] (iv) 
hindering drug inactivation and modification by bacterial 
enzymes[12] and (v) hijacking or inhibiting the bacterial metal 
acquisition system.[13] In this work, we focus on the latter and 
specifically scrutinize the interaction between Fe3+ and 
pyoverdine, the primary siderophore of P. aeruginosa.   
The growth and survival of P. aeruginosa requires iron, which is 
scarce in an aerobic environment due to the low solubility of its 
ionic forms at circumneutral pH and host-bound in the context 
of an infection. Hence, a competition for iron between host and 
bacteria takes place and often represents a prequel to 
virulence. In order to efficiently scavenge iron from the host, 
bacteria have developed siderophores: these low molecular-
weight iron chelators, produced under iron-starved conditions, 
possess a very high affinity for Fe3+ ions. Once loaded with iron, 
the metal-siderophore complexes are recognized by specific 
bacterial outer membrane transporters, which translocate 
them into the periplasm using energy-dependent active 
transport mechanisms.  
P. aeruginosa produces siderophores pyoverdine and 
pyochelin, whose respective specific outer membrane receptors 
are FpvA and FptA. It has been recently demonstrated that P. 
aeruginosa synthesizes pyochelin first but switches to 
pyoverdine when the concentration in iron becomes low, most 
likely because producing pyoverdine is more energy-
consuming.[14] Not only does pyoverdine present a much 
higher affinity for Fe3+ than pyochelin (log Kf (FeIII) = 30.8 vs 
17.2[15] and pFeIII = 27 vs. 16), but it is also produced in much 
larger amounts (at least 10-fold more).[16, 17] Besides, it has 
been shown that the FpvA transporter is not exclusively specific 
to its cognate pyoverdine but is able to transport pyoverdines 
from other Pseudomonas strains as well.[18] Even more 
strikingly, this transporter has recently been shown to 
internalize pyocins (bacterial proteins designed to inhibit the 
growth of competing strains), which are able to masquerade as 
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pyoverdines despite their much larger size.[19] Following this 
train of thought, designing pyoverdine analogs to flood the 
bacterial environment could (i) fool P. aeruginosa out of its 
energy economy mode, exposing it to attacks and (ii) bring it 
“gifts”, in the form of siderophore-grafted antibiotic moieties.  
The efficiency of this Trojan horse strategy in the context of 
siderophores is amply demonstrated by nature: albomycins, 
ferrimycins and salimycins are natural antibiotics produced by 
streptomycetes which combine a metal chelator (resp. partial 
ferrichrome, ferrioxamine B and tris-hydroxamate) and a toxic 
molecule via a linker (resp. serine, amide and dicarboxylic 
acid).[20] Emulating this approach, antibiotics grafted to 
synthetic mixed hydroxamate/catecholate siderophores have 
been shown since the early 1990’s to be internalized by several 
bacterial membrane transporters[21]  and to negatively impact 
bacterial growth.[22] The use of pyoverdine in drug delivery 
strategies (reviewed by Mislin et al[23]) was pioneered by 
Budzikiewicz et al.[24]: these researchers grafted ampicillin 
onto the amino groups of basic amino acids on the peptide 
chain of pyoverdines from ATCC27853 and ATCC13525 strains, 
in the hope that the siderophore moieties could provide a novel 
point of entry for the antibiotic into the periplasm of ampicillin-
resistant bacteria. Indeed, the compounds displayed high level 
of antibiotic activity, overcoming the bacteria’s resistance. In 
the wake of this pioneering work, the same authors grafted the 
antibiotic cephalexin to the arginine side chain of ATCC15692. 
The resulting compound triggered an increase in iron uptake, 
proving its successful ingress into the periplasm, but showed no 
antibiotic activity.[25]  This is likely due to the bulk of the grafted 
siderophore sterically inhibiting the recognition of the antibiotic 
moiety, and could potentially be solved using easily cleavable 
antibiotic-siderophore linkers; however, such fragile 
connections have been shown to severely limit the activity of 
Trojan-horse compounds when going from in vitro to in 
vivo.[26]  Indeed, the in vivo evaluation of the activity of Trojan-
horse compounds raises the difficulty to another level entirely, 
for several reasons. First is the lack of animal models mimicking 
human situations; recent efforts in this direction[27] do not yet 
include P. aeruginosa. Second, the impact of mature biofilms 
predating drug administration is problematic to evaluate, since 
the connection between iron acquisition and biofilm 
formation/preservation is far from clearly understood and 
standardized experimental conditions for effective testing have 
yet to be defined.[28] Finally, unexpected evasive tactics by 
bacteria can hinder potentially effective therapies: for instance, 
P. aeruginosa can evolve in-host to acquire iron from 
hemoglobin upon loss of pyoverdine production or 
functionality.[29] 
These issues highlight a major pitfall of the Trojan horse 
approach: the hybrid compounds being more than the sum of 
their parts, one part can negatively impact the recognition of 
the other. Since these detrimental collective effects are 
expected to be mainly steric in nature, designing smaller and 
simpler analogs of both the siderophore and antibiotic moieties 
appears a worthwhile strategy to limit such issues. Reducing the 
siderophore’s size and chemical complexity has the added 
incentive of making it more amenable to chemical synthesis. 
However, a rational simplification of the siderophore scaffold 
can only be carried out with a sufficient understanding of the 
role of pyoverdine’s structural motifs on the corresponding 
bacterial pathways, which is still very limited as of now.[20, 30]  
Indeed, while the discovery of pyoverdine (via its fluorescence 
properties) dates back to the end of the 19th century,[31]  its 
complete structure hasn’t been published until 1981.[32] 
Today, more than 100 pyoverdines, produced by different 
strains and species of Pseudomonas, have been identified.[33, 
34] While structurally different, these siderophores possess 
common features: (i) a conserved chromophore binds Fe3+ via a 
catecholate function; (ii) a peptidic moiety (linear or cyclic) 
composed of 6 to 14 amino acids interacts with Fe3+ via two 
hydroxamate and/or carboxylate functions and (iii) a strain- and 
growth condition-dependent acyl side-chain, whose purpose 
remains elusive, is attached to the chromophore. In a strategy 
to develop pyoverdine mimics with the tools of total organic 
synthesis, the chromophore ((1S)-5-amino-2,3-dihydro-8,9-
dihydroxy-1H-pyrimido-[1,2-a]quinoline-1-carboxylic acid) is 
the most challenging residue to synthesize, in no small part due 
to its delocalized positive charge and triple ring framework. In 
this work, we postulate that a catechol-like moiety, with a 
similar backbone but lacking either the positive charge or some 
of the rings, might act as a simple and convenient replacement 
– or at least help pinpoint the roles of these features in the 
interaction of pyoverdine with Fe3+ and the FpvA transporter, 
which would be invaluable for the rational design of antibiotics 
based on the pyoverdine scaffold. Herein, we apply molecular 
modeling methods (ab initio, molecular dynamics and docking) 
to the preliminary assessment of the validity of this strategy. We 
build on the expertise of our group which has, in the past few 
years, palliated the dearth of computational studies on bacterial 
siderophores by combining quantum chemistry, forcefield 
design and state-of-the art free energy simulations to study the 
structural properties of pyoverdines and their impact on 
recognition by the FpvA transporter[35, 36], and experimented 
with simple tris-catecholate ligands showing promising iron-
binding affinities.[37] In this paper, we follow a stepwise 
approach: (i) we extract the individual iron chelation capabilities 
of catecholate and hydroxamate moieties, (ii) investigate 
possible synergistic effects in the metal-binding affinities of 
model monocatecholate-bis-hydroxamate systems, (iii) check 
the influence of the peptide chain linking the chelating groups 
in pyoverdine analogs built thereupon and (iv) study the 
interaction of these analogs with the FpvA transporter. We 
expect each step of the way to provide insights for the design of 
simple yet functional mimics of the pyoverdine PAO1 
chromophore able to chelate Fe3+ and be transported through 
FpvA for therapeutic purposes. 
Methods 
For brevity, only the essential features of the computational 
pipeline employed are reported below. The full computational 
details for each method are provided in ESM. 
System preparation. The starting geometry for the reference 
pyoverdine PvdI (Fig. 1b) was taken from Protein Data Bank 
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entry 2W16, in which the pyoverdine is bound to its cognate 
FpvA transporter.[18]  
Spin states of siderophore-bound Fe3+. In ab initio calculations, 
[Fe3+L6] complexes were treated as high spin, open shell systems 
featuring a ferric ion with five unpaired electrons (S = 5/2) and 
a multiplicity of six; spin crossover was neglected (see ESM for 
justifications). 
Density functional theory (DFT) calculations. Among the 
numerous functionals tested on open-shell Fe3+ systems in the 
past decade, the hybrid B3LYP[38-40] and M06[41, 42] 
functionals tend to provide the most consistent results when 
multiple quantities (structure, properties, energetics, 
reactivity…) are evaluated simultaneously.[43-45]. The 6-31G* 
basis set, a verified compromise[46-49] between accuracy and 
computational cost in these systems, was used. B3LYP and M06 
were found to provide similar results on our systems (RMSD<0.3 
Å and Fe3+-O distances within 0.03 Å for optimized structures, 
2% difference in binding energies). Hence, only the B3LYP 
results are presented below, and the M06 results can be found 
in ESM.    
Ab initio binding energies. Binding energy was defined as the 
difference between the calculated energy of the complex and 
the sum of that of its isolated partners: Ebinding = Ecomplex - (EFe3+ + 
∑Eligand). For homogeneous complexes (Fe3+-L3) and neglecting 
collective effects, the per-ligand binding energies were 
estimated as follows: Eper_ligand = Ebinding/3. All binding energies 
were obtained on optimized geometries of the complexes and 
isolated cation and ligands. Basis set superposition errors 
(BSSE), which can reach 8% of binding energies in similar 
systems,[50, 51] were systematically corrected. 
Additional ab initio calculations. Zero-point, thermal and 
entropic corrections were added to the electronic energies to 
calculate gas-phase Gibbs free energies. The quantum theory of 
atoms in molecules[52, 53] (QTAIM) was used for the 
topological analysis of bond critical points (BCP) in the electron 
density at Fe···O bond paths.  
Molecular Dynamics (MD) Simulations. The AMBER99SB force 
field[54] was used for standard aminoacids. Nonconventional 
residues (chromophores and analogs, ornithine, side-chain-
branching lysine) required additional parameterization, which 
was achieved as described in our previous work.[35-37] In order 
to monitor the capacity of the different siderophores to bind 
and retain Fe3+, iron was treated noncovalently using the non-
bonded parameters of Giammona.[55] The systems were 
solvated in a truncated octahedral TIP3P water box with a buffer 
distance of 10 Å and neutralized with a minimal number of Na+ 
or Cl- ions.  
After a typical equilibration procedure (see ESM), MD 
simulations were performed at constant pressure of 1 bar and 
temperature of 300 K using periodic boundary conditions and 
PME long-range electrostatics.[56] Solvation free energies were 
computed using the MM-GBSA method. The conformational 
space explored using molecular dynamics simulations was 
clustered with the hierarchical agglomerative approach; the 
central structure of each cluster was minimized ab initio and the 
most stable candidate was retained. 
Docking. Docking calculations of (partially flexible) pyoverdine-
Fe3+ complexes onto the (rigid) FpvA transporter explored the 
volume defined by a cube with an edge length of 60 Å and 
centered on the experimental binding site. 
 
(a) 
 
(b) 
Fig. 1 (a) General pyoverdine structure. (b) Structure of PvdI from P. aeruginosa strain 
ATCC 15692. 
Results 
Pyoverdine analogs. Pyoverdine ATCC15692, produced by 
strains of P. aeruginosa PAO1 (Fig. 1b), is the archetype of the 
pyoverdine family, whose 100+ members comply with the 
general scaffold shown on Fig. 1a. It will be referred to as PvdI 
in the remainder of the text. Its partially cyclic peptide moiety is 
composed of eight amino acids, two of which are in a D 
configuration and two non-natural (hydroxy-formyl-ornithine). 
The chelation of Fe3+ is performed by the chromophore and the 
two ornithines, all nonsymmetrical bidentate ligands. The tris-
chelate Fe3+-PvdI complex thus formed presents a metallic 
center with an octahedral geometry. The arrangement of the 
three ligands around the cation can lead to many enantiomers 
which can be classified by the sense of the screw axis defined by 
the six donor atoms: left-handed helices are assigned the L 
configuration, while right-handed helices belong to the D 
configuration.[57] Pyoverdines known to be internalized by the 
FpvA transporter tend to present the following 
characteristics:[18] (i) the peptidic sequence starts with a D-
serine, (ii) the second amino acid is basic, (iii) the third residue 
is small, (iv) the first iron chelating amino acid is in the fourth 
position of the peptide sequence, (iv) the peptide sequence is 
partially cyclic, (v) the metal center is in a L configuration.  
Because of the complexity of the chromophore and non-
proteinogenic amino acids, very few synthetic routes towards 
pyoverdine have been proposed (including a single successful 
attempt at total synthesis[58]) and the endeavor remains 
challenging. In particular, the construction of the fused tricyclic 
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chromophore skeleton and the correct introduction of the 
double bond on the second chromophore ring require multiple 
steps, lowering yields and increasing costs. Triggered by the 
renewed interest for siderophore-based therapeutics in the 
context of accrued bacterial resistance, novel synthetic routes 
are currently being explored;[59] however, there remains a 
strong incentive for the rational simplification of the 
chromophore scaffold based on the understanding of its 
features. To this purpose, we designed three replacements 
units (namely CR1, CR2 and CR3) for the original chromophore 
CR0 (Fig. 2). All three retain the catechol functions, but reduce 
the number of rings to one or two and discard the positive 
charge of the chromophore and the chiral center at atom C1. In 
all three, the third ring is replaced by a glycine, whose nitrogen 
atom is positioned to replace either N12 (CR1, CR2) or N4 (CR3). 
CR1 and CR2 retain the substituent group at C5 but differ in their 
intrinsic rigidities via an optional second cycle; CR3 employs an 
amide function to simultaneously emulate the rigidity of the 
second cycle and the polar nature of the C5 substituent. CR2 has 
a chiral center whose configuration was not found to affect any 
of the results presented herein (see ESM for details). We 
subsequently introduce pyoverdine analogs aPvd1, aPvd2 and 
aPvd3, respectively built upon chromophore analogs CR1, CR2 
and CR3 and the peptide chain of PvdI. 
 
 
 
 
 
 
(a)  
 
 
 
 
 
(b)  
 
 
 
 
 
(c)  
 
 
 
 
 
(d)  
Fig. 2 Structure of the native chromophore CR0 of PvdI (a) and the three analogs under 
study: CR1 (b), CR2 (c), CR3 (d). 
Model systems. Pyoverdines bind iron though three bidendate 
functions, one catecholate and two hydroxamates. As such, 
they appear to represent a middle ground between 
enterobactin, the primary siderophore of E. coli which interacts 
with Fe3+ via three catecholate functions and is one of the most  
efficient natural binders of ferric ions known to date (pFeIII = 
35.5, log Kf (FeIII) = 49)[60], and desferrioxamine B, siderophore 
of Streptomyces, which employs three hydroxamate functions 
and shows a lesser affinity for iron (pFeIII = 26.6, log Kf (FeIII) = 
31).[61] To rank of the complexing abilities of the hydroxamate 
and catecholate ligands and compare the pyoverdine-Fe3+ 
interactions to simple references, we have built simple tris-
catecholate (Fe3+(Cat2-)3), tris-hydroxamate (Fe3+(Aha-)3) and 
pyoverdine-like (Fe3+(Cat2-)(Aha-)2) model systems (Fig. 3).  
Furthermore, to gain insight into the role of the chromophore 
and its analogs, we have replaced the catechol motif in these 
model systems by CR0, CR1, CR2 or CR3, yielding model systems 
Fe3+(CR0-)3, Fe3+(CR12-)3, Fe3+(CR22-)3, Fe3+(CR32-)3, Fe3+(CR0-
)(Aha-)2, Fe3+(CR12-)(Aha-)2, Fe3+(CR22-)(Aha-)2 and Fe3+(CR32-
)(Aha-)2. The Aha- ligand being nonsymmetrical, many 
conformations of the Fe3+(Aha-)3 complex can theoretically 
being formed; we have limited ourselves to the configuration 
presenting a pseudo-C3 symmetry. For the remaining 
Fe3+(X)(Aha-)2 model systems, the orientation of the Aha- units 
was kept identical to PvdI. The original exocyclic architecture of 
the Fe3+-PvdI complexation center were kept, and all complexes 
are in their L configuration.  
 
 
(a)  (b)  
 
(c)  
Fig. 3 Structures of model tris-catecholate (a), tris-hydroxamate (b) and pyoverdine-like 
monocatecholate-bis-hydroxamate (c) systems binding Fe3+. 
Iron-binding properties. The efficacy of pyoverdine derivatives 
as siderophores can be evaluated from their Fe3+-binding 
properties. To this end, ab initio calculations were performed 
on the most stable structures of all analogs and model systems. 
The effects of conformational flexibility and solvation on the 
binding of iron were explored with 50 ns of MD simulations 
coupled with MM-GBSA calculations. 
Fig. 4 Fe3+···O distances in pyoverdine and analogs, colored by oxygen type. 
The ab initio Fe3+···O distances for every complex (Fig. 4) fall 
within a 1.93 - 2.20 Å range indicating a strongly coordinated 
interaction between the three bidentate ligands and the ferric 
ion. The distances reported for the tris-catecholate complex are 
close to those obtained by X-Ray analysis[62], validating the 
methodology on other systems for which no such experimental 
data is available.  
All tris-catecholate systems (Fe3+(Cat2-)3, Fe3+(CR0-)3, Fe3+(CR12-
)3, Fe3+(CR22-)3 and Fe3+(CR32-)3) adopt the expected C3 
symmetry. However, unlike the other systems, each ligand in 
Fe3+(CR0-)3 features two strikingly non-identical Fe3+···O 
distances. Interestingly, distances in Fe3+(CR0-)3 are comparable 
to those encountered in Fe3+(Aha-)3, in which the Fe3+···O=C 
interactions are longer than Fe3+···O-N. Since Fe3+(CR12-), 
Fe3+(CR22-) and Fe3+(CR32-) do not exhibit this behavior, it is 
most likely due to the presence of the additional positive charge 
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Fig. 5 Covalent/ionic character of the Fe3+···O interactions in (left) tris-catecholate/tris-hydroxamate model systems; (center) monocatecholate-bis-hydroxamate model systems; 
(right) PvdI and analogs, as defined by the Laplacian of the electron density Ñ2r and the energy density Hr at the BCP. Stars identify the interactions made by the native catecholate 
chromophore of PvdI (CR0).
on the third chromophore ring rather than to the asymmetry of 
the chromophore analogs compared to catechol. These 
observations apply to mixed hydroxamate/catecholate model 
systems as well. As a general principle, the replacement of 
catecholates by hydroxamates eases the steric hindrance and 
alleviates the electronic repulsion brought about by the 
former’s bulk and -2 net charge, resulting in Fe3+···O interactions 
that are shorter for the remaining catecholate and longer for 
the hydroxamates. However, as for the tris-catecholates, 
Fe3+···O interactions within a catecholate ligand remain grossly 
equivalent in all models except Fe3+(CR0-)(Aha-)2. 
The conformational strain induced by the peptide chain results 
in nonequivalent O···Fe3+ distances within catecholate moieties 
for PvdI and all its analogs aPvd1-3. However, in PvdI, the 
catecholate and hydroxamate Fe3+···O distances are a near-
perfect match, resulting in a pseudo-C3 arrangement of the 
ligands around the metal ion despite their different natures; 
conversely, in the analogs, the catecholate Fe3+···O distances are 
consistently shorter than their hydroxamate counterparts just 
like in the monocatecholate-bis-hydroxamate model systems. 
To correlate these structural results with the relative nature and 
strengths of individual Fe3+···O interactions, topological 
analyses of bond critical points (BCP) were performed. The 
Laplacian Ñ2r of the electron density r at the BCP reveals the 
balance of ionic and covalent characters for the bond: larger 
(resp. smaller) values denote a marked covalent (resp. ionic) 
character.[53] A complementary information can be extracted 
from the energy density Hr, which can be decomposed into the 
sum of a repulsive kinetic term Gc and an attractive potential 
term Vc: the latter tends to dominate interactions of marked 
covalent character, yielding negative Hr values. All systems 
under study feature negative (albeit small) Hr values at the BCP, 
confirming the partly covalent character of Fe3+···O interactions 
(Fig. 5). 
The specificity of Fe3+(CR0-)3 among tris-catecholate systems 
again becomes apparent: while the latter feature six equivalent 
Fe3+···O bonds characterized by interchangeable (Ñ2r, Hr) 
values, the former shows a clear split in the nature of the two 
iron-oxygen interactions of each ligand (Fig 5, left panel). The 
circulation of the additional positive charge borne by CR0- drives 
one iron-oxygen interaction towards a more covalent behavior 
(larger absolute values of Hr and smaller Ñ2r) while the other 
becomes weaker and more ionic. Intriguingly, from the 
standpoint of BCP, Fe3+(CR0-)3 is very close to Fe3+(Aha-)3, in 
which the nitrogen-bound oxygen of each ligand forms a much 
more covalent bond to Fe3+ than its carbon-bound counterpart.  
Replacing catecholates with hydroxamates tends to strengthen 
catecholate-Fe3+ and weaken hydroxamate-Fe3+ interactions 
compared to the tris-systems (Fig. 5, center panel); the 
weakening of the hydroxamate Fe3+···O-N bond brings it closer 
to its more ionic Fe3+···O-C counterpart. Again, Fe3+(CR0-)(Aha-)2 
is an exception to this rule: with comparatively strong 
hydroxamate and weak catecholate interactions to Fe3+, it is 
once again closer to Fe3+(Aha-)3 than to Fe3+(Cat2-)(Aha-)2. 
The presence of the peptide chain in PvdI and its aPvd analogs 
(Fig. 6, right panel) has much more impact on the interaction of 
Fe3+ with the catecholates than with the hydroxamates. While 
the flexible hydroxamates can adopt an optimal arrangement 
around Fe3+ despite the constraints introduced by the cyclic 
peptide chain, the distal chelating oxygen of the more rigid 
catecholates is pulled away from the metal center, weakening 
the corresponding interaction. Yet again, the BCP character of 
Fe3+-PvdI is comparable to that of Fe3+(Aha-)3, while Fe3+-aPvd 
mimics Fe3+(Cat2-)(Aha-)2. PvdI is remarkable in its ability to 
equalize the metal chelating properties of ligands of very 
different chemical natures, possibly to achieve a tradeoff 
between affinity for the metal ion and preservation of enough 
structural complexity to ensure other functions (recognition by 
transporters…). 
 
Fig. 6 Left: ab initio Fe3+-binding energies of tris-catecholates (green), tris-
hydroxamate (red), monocatecholate-bis-hydroxamates (blue) and pyoverdine 
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analogs (yellow). Lighter bars represent binding energies calculated as the sum of 
individual ligand binding energies. Right: MM-GBSA Fe3+-binding enthalpy in the 
gas phase (black bars, left axis) and Fe3+-binding free energies (grey bars with 
errorbars, right axis) of pyoverdine and analogs. 
A similar picture emerges from the Fe3+ interaction energies 
(Fig. 6). Tris-catecholates bind Fe3+ more strongly than tris-
hydroxamates, with the notable exception of native 
chromophore CR0- which again tends to behaves more like the 
latter than the former. As expected, monocatecholate-bis-
hydroxamates represent a middle ground. In fact, if one 
evaluates the individual interaction energies of the catecholate 
and hydroxamate groups as the third of the interaction energies 
of the tris-complexes and sum their contributions in the 
monocatecholate-bis-hydroxamates, the correct interaction 
energies can be predicted within a 4% error margin: collective 
effects (which tend to stabilize the complexes) thus appear 
quite limited. In pyoverdine analogs, the deviation from the sum 
of individual ligand binding energies is larger and in the opposite 
direction: the conformational strain induced by the peptide 
chain results in unfavorable collective effects. Surprisingly, 
these are much more strongly marked for the native pyoverdine 
than for its analogs, corroborated by gas-phase binding 
enthalpy values obtained from MM-GBSA calculations (Fig. 5, 
right panel) in which PvdI appears less strongly bound than the 
latter. A look at the frontier molecular orbitals (see ESM) reveals 
that the lowest unoccupied molecular orbital (LUMO) and the 
highest occupied molecular orbital (HOMO) of Fe3+-aPvd 
systems are localized on the metal ion and the chromophore, 
respectively, which is indicative of a charge transfer from 
chromophore to metal. This behavior, also seen in Fe3+(Cat2-)3, 
is in agreement with previous studies of related systems.[50, 
51] On the other hand, Fe3+-PvdI frontier orbitals are much 
more complex and involve the metal ion and its three ligands 
simultaneously, as in Fe3+(Aha-)3. The hydroxamates which play 
a role in the HOMO and LUMO of  Fe3+-PvdI do not contribute 
to either frontier orbital of Fe3+-aPvd. The larger HOMO-LUMO 
gap in Fe3+-PvdI compared to Fe3+-aPvd (similar to that of 
Fe3+(Aha-)3 vs Fe3+(Cat2-)3) confirms the lower Fe3+ binding 
affinity of PvdI; it also provides yet another confirmation of the 
remarkable similitude of PvdI and (Aha-)3 for the complexation 
of Fe3+. 
Fig. 7 Radial distribution functions of water molecules around (left) and kernel density 
estimations of (RMSD, radius of gyration) pairs for (right) PvdI and analogs. 
Intriguingly, upon solvation, stabilities are reversed and PvdI 
becomes the strongest binder by 40-50 kcal mol-1, in agreement 
with the pFe values measured in our previous work[37] and 
hinting at particularly favorable interactions with water; 
however, as we will see below, the binding affinities of the 
analogs remain well within the range of efficient siderophores. 
 
Conformational dynamics of the siderophores. We now focus 
on the influence of the conformational dynamics of the 
siderophores and neighboring water on Fe3+ binding. The radial 
diffusion functions (rdf) of water around the metal cation are 
represented on Fig. 7 left panel. The first peak’s remote position 
(>4 Å) and small width hint at a strongly structured first water 
layer, but which cannot penetrate the metal’s first coordination 
sphere. PvdI shows a remarkable long-distance structuration of 
water, with clearly visible second- and third-layer peaks, which 
could explain the added stability of solvated Fe3+-PvdI seen 
earlier. aPvd3 also achieves a similar long-range ordering of 
water, whereas aPvd1 and aPvd2 have almost no impact on 
water molecules beyond their (rather sparse) first hydration 
layer. Regarding the stability difference between Fe3+-PvdI and 
Fe3+-aPvd3 in water, it appears that the entropic penalty 
associated with the ordering of multiple water layers is 
obviously not as well compensated by favorable interactions 
with water in the latter compared to the former; this could be 
due to the additional hydrogen-bonding functions on the 
chromophore substituent chain at C5. 
The distributions of RMSD to the average structure and radius 
of gyration (Rg) indicate relatively rigid and compact structures 
for all systems under study (Fig. 7, right panel). PvdI-Fe3+, the 
bulkiest of all siderophores studied herein, features contained 
RMSDs and a compact distribution of radii of gyration (Rg), 
indicative of an enhanced conformational stability both at the 
local and global levels. Despite sharing CR0-‘s bond pathway to 
Ser3, CR12- lacks the chiral C1 atom and second ring of the 
former, resulting in an enhanced plasticity both at the local and 
global levels. aPvd2, the only analog sporting a double-ring 
chromophore, has similar spatial extents and undergoes little 
large-scale deformations (Rg), but is markedly more flexible at 
the local level (RMSD). aPvd3 is significantly more compact than 
the other pyoverdines and very rigid despite the absence of the 
second cycle and the larger number of carbon atoms between 
catecholate and peptide chain. Interactions within the 
siderophores obviously play an important role in amplifying or 
curbing the spatial extents and flexibility inherent to their 
respective chemical formulas. Decomposing each residue’s 
contribution to conformational flexibility (see ESM) reveals the 
dynamics of Arg4 to be the most affected upon chromophore 
replacement. Indeed, its lengthy side chain and central position 
make it the perfect adjustment variable for adapting the 
peptide chain to different chelating group setups. In aPvd1 and 
aPvd2, Arg4 is located rather close to the metal center (Fig. 8 
left panel), where repulsion between the charged guanidinium 
(Gdm+) and the metal occurs. This results in added plasticity for 
the arginine side chain (Fig. 8, center panel); however, the plane 
of the Gdm+ group remains at all times orthogonal to the 
chromophore plane (Fig. 8, right panel), most likely because of 
transient stabilizing interactions between the chromophore p 
electrons and Gdm+. This is in contrast with PvdI, in which the 
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Fig. 8 Left: Distributions of (left) the ratio of the distance of Arg4 Cz to Fe3+ over the distance of Arg4 Cz to the catecholate center of mass; (center) the RMS fluctuations of Arg4 
atoms; (right) the angle between the planes of the Arg4 guanidinium group (Gdm+) and the catecholate, for pyoverdine and its analogs
additional positive charge on the chromophore prevents such 
interactions and results in these planes being nearly stacked. In 
addition, the rigidity of the conjugated tri-cyclic scaffold keeps 
Arg4 further away from the metal center, where it is more 
accessible to other molecules – an important point since Arg4 
plays a major role in the recognition of pyoverdine by 
itsmembrane transporter.[35] Through a combination of its 
amide scaffold, simultaneously longer and more rigid than 
those of the other analogs,  aPvd3 achieves a much closer match 
with PvdI with respect to the positioning and flexibility of Arg4. 
The effect of the PvdI chromophore charge is partially 
emulated: although T-shaped Gdm+/chromophore 
conformations still exist, stacked conformations are now also 
encountered. Hence, both charge and conformational rigidity 
can be used to the same effect in fine-tuning the behavior of 
Arg4. 
  
Recognition by the FpvA transporter. Docking calculations have 
been performed to predict whether or not the pyoverdine 
analogs interact with the FpvA transporter in the same way PvdI 
does. In their seminal study on the binding of different 
pyoverdine strains to FpvA, Greenwald et al observed that the 
binding mode of the siderophore chelating groups onto FpvA 
was much more conserved across pyoverdine variants than that 
of the peptide chain, in line with the fact that the main 
variations between pyoverdine strands occur in the sequence of 
the peptide chain.[18] Notably, residue Arg204 of the 
transporter lid is brought in the vicinity of Fe3+ by a 
conformational transition of the corresponding loop upon 
binding of the siderophore to the transporter, while Val229 and 
Tyr231 make contact with the chromophore and the first 
hydroxamate. In our previous investigation, we showed that the 
specific recognition events involving the peptide chain mainly 
take place with the transporter lid loops during the phase 
leading to binding[35] Nevertheless, contacts can be observed 
in the bound state between Arg4 on the pyoverdine chain and 
residue Asp597 of the so-called L7 loop of the transporter, as 
well as with Asn228 via a transient hydrogen bond. We now 
examine whether these trends persist in our analogs. 
The top-scoring docked structures of PvdI, aPvd1, aPvd2 and 
aPvd3 are shown on Fig. 9. Reassuringly, the top scoring hit for 
the docking of PvdI onto FpvA shows a near-perfect 
superimposition with the experimental structure and a score of 
-10.5 kcal mol-1, quite close to our previous determination using 
a much more accurate methodology.[35] Although somewhat 
lower (-8.3, -9.3 and -9.8 kcal.mol-1 for aPvd1, aPvd2 and aPvd3, 
respectively), the predicted affinities of our analogs for FpvA are 
compatible with efficient recognition and binding; however, the 
corresponding binding poses are quite different from that of 
PvdI. For aPvd1, docked structures yield binding energies from -
8.3 to -6.2 kcal.mol-1 and the top-scoring structures is the 
closest to PvdI. Since the metal center is shifted outwards and 
is somewhat more exposed to the solvent, the interactions 
between Arg204 and Fe3+ and between Asn228 and the 
backbone of Arg4 cannot take place; however, the interaction 
between Asp597 and Arg4 is preserved. For aPvd2, the binding 
energies fall within a -9.3 to -6.4 kcal.mol-1 range, but none of 
the docking solutions come close to the binding mode of PvdI 
due to the very different relative orientation of the 
siderophores. The chelation center is exposed to the solvent 
and does not directly interact with any residue on FpvA; none 
of the aforementioned “canonical” interactions exist. Binding 
energies for aPvd3 vary between -9.8 and -8.1 kcal.mol-1. 
Although the global shape and volume of the top scoring 
structure are similar to those of PvdI, its position relative to 
FpvA is flipped just like aPvd2. The metallic center is oriented 
towards the extracellular side of the transporter, is exposed to 
the solvent and exhibits none of the previously mentioned 
metal/chromophore-FpvA interactions. However, looking at the 
lower-rank docking poses reveals the existence of a 
conformation of aPvd3 with an affinity of -8.5 kcal mol-1, a low 
RMSD to the native PvdI binding pose and which only lacks the 
interaction between Asn228 and the carbonyl of Arg4. 
To conclude, aPvd1 and aPvd3 appear to have the ability to bind 
FpvA with conformations akin to that of native PvdI and could 
presumably be recognized and internalized by the transporter, 
although the coexistence of other, very different binding modes 
raises a selectivity issue.  
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Fig. 9 Superimposition of the docking poses (labeled by their respective scores) of pyoverdine and analogs (yellow) onto the crystal structure of PvdI (red) bound to FpvA (green 
cartoons, with aminoacid sidechains involved in pyoverdine recognition as green sticks). Unless otherwise specified, the top-ranking pose is shown
Discussion 
The goal of this paper is the preliminary assessment, using 
molecular modeling methods, of relatively simple synthetic 
scaffolds able to mimic the pyoverdine chromophore in future 
antibacterial  drugs based on the Trojan horse strategy. 
Thespecifications are fourfold: (i) chelation of iron with high 
affinity, (ii) recognition and binding by FpvA, (iii) propagation of 
the binding event signal through the outer membrane to the 
periplasm-located TonB subsystem which triggers the 
internalization and (iv) possibility of grafting antibiotic moieties 
without hindering recognition through unfavorable steric 
effects. 
 
Metal ion binding affinities. Hay and coworkers have shown the 
affinity of tris-catecholamides for Fe3+ to be considerably 
diminished by deviations from the ideal chelating geometry due 
to steric strain.[63] Ab initio calculations on our analogs in the 
gas phase show a similar trend: overall, the replacement of the 
rigid and bulky native CR0- chromophore by the simpler and 
more flexible CR[1-3]2- analogs allows shorter (hence stronger) 
iron-catecholate interactions. Although the additional negative 
charge on CR[1-3]2- compared to CR0- slightly destabilizes 
hydroxamate-iron interactions via electronic repulsion, the 
overall balance remains in favor of our analogs. The cyclic 
peptide chain considerably enhances the effect by introducing 
an interdependence in the relative positions and orientations of 
the chelating groups, which the rigid CR0- is much less likely to 
compensate than the more flexible CR[1-3]2- mimics. This effect 
has also been observed, on bacterial siderophores bacillibactin 
and enterobactin, by Dertz and coworkers.[64] Altogether, in 
the gas phase, the replacement of the native chromophore very 
clearly favors the metal-binding affinity.  
Interestingly, when taking solvation into account, the picture is 
reversed: while the three proposed analogs can definitely 
chelate Fe3+ in an aqueous medium (as attested by the short and 
stable Fe3+×××O distances seen in MD simulations despite the 
absence of bonded interactions), they do so with less affinity 
than PvdI. In our previous work,[37] we have found a very good 
linear correlation between MM-GBSA binding free energies and 
experimental pFe values on similar pyoverdine analogs; 
applying this relationship to the binding free energies computed 
herein yields pFe values of 24 to 25 for all analogs under study, 
as compared to 27 for PvdI. The superior affinity of PvdI for iron 
arises from more favorable solvation electrostatic energies, 
linked to the better structuration of the water layers around the 
metal ion: the average number of water molecules in direct 
contact with Fe3+ is 8.80 and 8.88 in aPvd1 and aPvd2, vs. 9.23 
in PvdI. The interaction with water is obviously able to alleviate 
the incompatibilities between the preferred geometries of the 
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peptide chain and metal-binding ligands observed in the gas 
phase. In our previous work, we had already concluded that the 
interaction of pyoverdine strains with water was more 
discriminating than their interactions with the FpvA transporter, 
and represented the dominant contribution to the binding free 
energy;[35] the same obviously holds true for the pFe of 
pyoverdines and analogs.  
However, despite their lower affinity for Fe3+ than PvdI, the 
predicted pFe values of our analogs remain quite high – similar 
to that of tris-hydroxamate desferrioxamine B, native 
siderophore of Streptomyces (pFe=26.6) and much higher than 
the best analog considered in our previous study[37] (pFe=21) 
despite the theoretically greater Fe3+ affinity of the latter’s tris-
catecholate nature. aPvd1, aPvd2 and aPvd3 thus appear to 
meet the first of the criteria enumerated at the start of this 
section (which we will now strive to confirm experimentally).  
 
Accommodating chelation electronics and conformational 
strain. The +1 charge borne by the native pyoverdine 
chromophore CR0- considerably complexifies the synthesis of 
analogs built thereupon. Hence, the evaluation of its relevance 
and purpose has been a key question from the onset of the 
study. Our ab initio calculations have shown that, unlike the 
Cat2- model ligand and its three mimics (CR12-, CR22- and CR32-), 
the properties of CR0- tend to change once integrated into a 
monocatecholate-bis-hydroxamate system. Despite the fact 
that CR0- chelates Fe3+ via its two O- atoms, the resulting 
interaction is dissymmetrical, with properties reminiscent of 
those observed upon complexation by a hydroxamate moiety: 
the Fe3+(CR0-)(Aha-)2 system is closer to Fe3+(Aha-)3 than 
Fe3+(Cat2-)(Aha-)2, whereas Fe3+(CRX2-)(Aha-)2 systems remain 
closer to the latter. This is in no small part due to the 
delocalization of the additional positive charge over the 
chromophore ring system, which affects the electrostatic and 
dispersive properties of the chromophore and weakens the 
Fe3+×××O- interactions by disrupting the electronic density at 
bond-critical points in a dissymmetrical way. The result is a 
ligand which combines the electronic effects of hydroxamate 
(lower iron binding affinities) with the additional bulk and 
rigidity of a substituted catecholate, limiting the conformational 
plasticity of the entire siderophore; this versatility is probably 
essential in the recognition and transport of the siderophore by 
the TonB machinery. 
In aPvd1, aPvd2 and aPvd3, the conformational strain induced 
by the pyoverdine peptide chain on the placement of the 
chelating groups is also able to split the degeneracy of the 
catecholate Fe3+×××O bonds; however, they remain much 
stronger than hydroxamate-Fe3+ interactions, whereas PvdI 
retains its striking similarity to a tris-hydroxamate siderophore. 
Part of the explanation for this discrepancy lies in the existence 
of an intramolecular interaction between CR0- and the Gdm+ 
group of Arg4 of the peptide chain. The positive charge on CR0- 
limits the volume spanned by the Gdm+ group and locks its 
position above the chromophore in a stacked conformation 
which rigidifies the peptide chain, helping to preserve relatively 
long (and weak) catecholate Fe3+×××O bonds. This rigidity favors 
the structuration of hydration layers around the metal center, 
counterbalancing the entropic penalty with a stabilizing 
hydrogen bond network.  
In aPvd1 and aPvd2, Arg4 interacts perpendicularly to the 
catecholate function and much closer to the metal center, 
limiting the ingress of water molecules and resulting in a weaker 
binding of Fe3+. Interestingly, aPvd3 comes the closest to 
mimicking the Arg4-chromophore interactions found in PvdI, 
even though CR22- appears the closest to CR0- both structurally 
and in terms of flexibility. This is most likely due to the 
combination of a compact yet rigid chromophore analog CR32- 
and a longer linker length between catecholate and Arg4, which 
hinders the access of Gdm+ to the vicinity of the metal center. 
The combination of chromophore rigidity and added electronic 
charge thus marks PvdI out as a “sweet spot” in the compromise 
between an efficient chelation environment and a favorable 
conformation of the peptide chain. However, the promising 
metal-binding affinity and solvent-ordering capacity of aPvd3 
proves that the effect of the additional charge can be partly 
emulated via controlled steric effects. 
 
The conundrum of transporter recognition specificity. Because 
iron is usually a very scarce resource, coexisting bacterial 
colonies are in constant competition to secure their 
requirements.[65] To gain the leading edge in this competition, 
bacteria would need to recognize and internalize siderophores 
from as many other bacterial strains as possible, while 
synthetizing highly specific native siderophores that as few as 
possible other bacterial strains can steal. These two antinomic 
statements place very high requirements on the recognition 
process by membrane transporters: recognizing native and 
“foreign” siderophores at the same site with the same 
mechanism is not possible unless both siderophores are quite 
similar, in which case the native siderophore is also easily 
recognized and “stolen” by other bacterial strains. 
All pyoverdines recognized by FpvA (native or otherwise) 
chelate Fe3+ using chromophore CR0- and two hydroxamate 
residues; the position of the chromophore at the binding site 
and the interactions it forms with FpvA are conserved. This led 
Greenwald et al[18] to postulate that FpvA is specific for only 
one conformation of the iron-binding part of pyoverdine. Since 
then, however, couplings between the variable peptide chain 
and the immutable chromophore have come to light, revealing 
the complexity of the recognition patterns of membrane 
transporters such as FpvA and how little they are understood. 
For instance, we have previously shown that the peptide chain, 
which differs between pyoverdines in length, overall chemical 
character and cyclicity, impacts the position and conformational 
freedom of metal-binding moieties.[35] More recently, we have 
shown that FpvA can recognize and bind both L- and D-type 
stereoisomers of pyoverdines (defined based on the 
handedness of the octahedral arrangement of ligand 
arrangements around Fe3+) with a ratio of affinities that 
depends on the pyoverdine strain.[36] The docking calculations 
performed in this paper predict that, despite their rather 
different chemical natures, binding modes comparable to that 
of PvdI exist for aPvd1 and aPvd3, with affinities which, albeit 
lower than that of the native siderophore, are comparable to 
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those of other pyoverdine strains such as DSM50106 which are 
recognized by FpvA. [35] The compact size of aPvd3 accounts 
for the coexistence of several poses within a small energy range, 
raising possible selectivity issues; however, this behavior is also 
seen (to a lesser degree) for the native siderophore and is 
probably alleviated by the conformational selection which takes 
place during the first stages of the recognition by FpvA. [35] This 
compactness also opens the possibility of grafting additional 
antibiotic moieties to aPvd3 while still fitting in the FpvA binding 
pocket, an important feature for a Trojan horse scaffold. 
Considering Arg4’s importance in the recognition and binding of 
pyoverdines by FpvA, the similarity of this residue’s 
conformational behavior in aPvd3 and PvdI is promising. In 
some siderophores, cationic aminoacids with long sidechains 
such as Lys or Arg have been shown to efficiently displace 
structured water layers and hydrated ions from interfaces, 
preconditioning them for binding.[66-68] Indeed, we previously 
observed a similar mechanism for the binding of PvdI to 
FpvA,[35] and the evidence gathered from this work suggest 
that aPvd3 should also be concerned. In addition, based on our 
finding that the position of Arg4 is strongly influenced by the 
additional positive charge on CR0-, we suggest that Arg4 (or a 
similarly placed positively charged residue) could act as a 
vanguard for the chromophore’s positive charge, allowing the 
indirect recognition of this feature by FpvA during the initial 
phase of the binding process; mimicking the conformational 
properties of Arg4 could possibly favor recognition even in the 
absence of this additional charge. Finally, the absence in our 
analogs of the two simultaneous contacts between Arg4 and the 
transporter observed in PvdI (at the Gdm+ extremity via Asp597 
and at the backbone via Asn228) does not necessarily raise 
issues: both aPvd1 and aPvd3 retain the contact to the 
transporter L7 loop via Asp597 also seen in non-native 
pyoverdines, known to be transported by FpvA, featuring 
different (positively charged) residues at position 4. [18] 
Concluding remarks 
In this work, we provide evidence that while the positive charge 
and the rigidity of the chromophore scaffold are crucial both for 
the binding of iron and the recognition by FpvA, their effects can 
be effectively emulated using other chemical functions. Indeed, 
our calculations predict pyoverdine analog aPvd3 to be a 
promising candidate on both accounts simultaneously. The 
experimental validation of these results and the optimization of 
this “lead” scaffold, much more amenable to synthesis than the 
native pyoverdine chromophore, are the next logical steps in 
our investigation. However, it should be kept in mind that 
pyoverdine fulfills many more roles than just scavenging iron (as 
an example, it regulates the expression of at least three 
virulence factors.[69, 70]) The impact of our analogs on these 
additional functions is, naturally, beyond the scope of this 
limited study. Nevertheless, through the latter, we hope to 
convey the message that the same structural and 
conformational polymorphism which powers such a broad array 
of simultaneous functions also offers great potential for the 
future design of pyoverdine mimics for therapeutic purposes.  
Acknowledgements The authors thank Région Picardie for financial support 
(SIDERBACT grant - Projets Régionaux Structurants 2011). The calculations 
presented in this work were performed using HPC resources from the 
MATRICS computing platform of Université de Picardie Jules Verne. 
References 
 
 
1. Zilberberg MD, Shorr AF (2013) J. Hosp. Med. 8:559-563. 
2. Croughs PD, Li B, Hoogkamp-Korstanje JA, Stobberingh E, 
Antibiotic Resistance Surveillance G (2013) Eur. J. Clin. 
Microbiol. Infect. Dis. 32:283-288. 
3. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, 
Srinivasan A, Kallen A, Limbago B, Fridkin S, National 
Healthcare Safety Network T, Participating NF (2013) 
Infect. Control. Hosp. Epidemiol. 34:1-14. 
4. Nations U. Draft political declara-tion of the high-level 
meeting of the General Assembly on antimicrobial 
resistance. 2016; Available from: http:// 
www.un.org/pga/71/wp-content/uploads/ 
sites/40/2016/09/DGACM_GAEAD_ 
ESCAB-AMR-Draft-Political-Declaration- 1616108E.pdf. 
5. Brickner SJ, Barbachyn MR, Hutchinson DK, Manninen PR 
(2008) J. Med. Chem. 51:1981-1990. 
6. Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, 
Fischetti VA, Foster S, Gilmore BF, Hancock RE, Harper D, 
Henderson IR, Hilpert K, Jones BV, Kadioglu A, Knowles D, 
Olafsdottir S, Payne D, Projan S, Shaunak S, Silverman J, 
Thomas CM, Trust TJ, Warn P, Rex JH (2016) Lancet Infect. 
Dis. 16:239-251. 
7. de la Fuente-Nunez C, Reffuveille F, Fernandez L, Hancock 
RE (2013) Curr. Opin. Microbiol. 16:580-589. 
8. de la Fuente-Nunez C, Reffuveille F, Haney EF, Straus SK, 
Hancock RE (2014) PLoS Pathog. 10:e1004152. 
9. Li XZ, Ma D, Livermore DM, Nikaido H (1994) Antimicrob. 
Agents Chemother. 38:1742-1752. 
10. Poole K, Srikumar R (2001) Curr. Top. Med. Chem. 1:31-57. 
11. Zgurskaya HI, Lopez CA, Gnanakaran S (2015) ACS Infect. 
Dis. 1:512-522. 
12. Munita JM, Arias CA (2016) Microbiol. Spectr. 4:VMBF-
0016-2015. 
13. Chandrangsu P, Rensing C, Helmann JD (2017) Nat. Rev. 
Microbiol. 15:338-350. 
14. Dumas Z, Ross-Gillespie A, Kummerli R (2013) Proc. Biol. 
Sci. 280:20131055. 
15. Zheng T, Nolan EM (2012) Metallomics 4:866-880. 
16. Hider RC, Kong X (2010) Nat. Prod. Rep. 27:637-657. 
17. Brandel J, Humbert N, Elhabiri M, Schalk IJ, Mislin GL, 
Albrecht-Gary AM (2012) Dalton Trans. 41:2820-2834. 
18. Greenwald J, Nader M, Celia H, Gruffaz C, Geoffroy V, 
Meyer JM, Schalk IJ, Pattus F (2009) Mol. Microbiol. 
72:1246-1259. 
19. White P, Joshi A, Rassam P, Housden NG, Kaminska R, Goult 
JD, Redfield C, McCaughey LC, Walker D, Mohammed S, 
Kleanthous C (2017) Proc Natl Acad Sci U S A 114:12051-
12056. 
20. Budzikiewicz H (2001) Curr. Top. Med. Chem. 1:73-82. 
21. Ghosh M, Miller MJ (1996) Bioorg. Med. Chem. 4:43-48. 
22. Mies KA, Gebhardt P, Mollmann U, Crumbliss AL (2008) J 
Inorg Biochem 102:850-861. 
23. Mislin GL, Schalk IJ (2014) Metallomics 6:408-420. 
 11 
24. Kinzel O, Tappe R, Gerus I, Budzikiewicz H (1998) J. 
Antibiot. 51:499-507. 
25. Kinzel O, Budzikiewicz H (1999) J. Pept. Res. 53:618-625. 
26. Szebesczyk A, Olshvang E, Shanzer A, Carver PL, Gumienna-
Kontecka E (2016) Coord. Chem. Rev. 327-328:84-109. 
27. Pletzer D, Mansour SC, Wuerth K, Rahanjam N, Hancock RE 
(2017) mBio 8: 
28. Post SJ, Shapiro JA, Wuest WM (2019) MedChemComm 
10:505-512. 
29. Marvig RL, Damkiaer S, Khademi SM, Markussen TM, Molin 
S, Jelsbak L (2014) mBio 5:e00966-00914. 
30. de Carvalho CC, Fernandes P (2014) Front. Microbiol. 
5:290. 
31. Jordan EO (1899) Bot. Gaz. 27:19-36. 
32. Teintze M, Hossain MB, Barnes CL, Leong J, van der Helm D 
(1981) Biochemistry 20:6446-6457. 
33. Budzikiewicz H (2004) Fortschr. Chem. Org. Naturst. 87:81-
237. 
34. Meyer JM, Gruffaz C, Raharinosy V, Bezverbnaya I, Schafer 
M, Budzikiewicz H (2008) Biometals 21:259-271. 
35. Bouvier B, Cezard C, Sonnet P (2015) Phys. Chem. Chem. 
Phys. 17:18022-18034. 
36. Bouvier B, Cezard C (2017) Phys. Chem. Chem. Phys. 
19:29498-29507. 
37. Antonietti V, Boudesocque S, Dupont L, Farvacques N, 
Cezard C, Da Nascimento S, Raimbert JF, Socrier L, Robin TJ, 
Morandat S, El Kirat K, Mullie C, Sonnet P (2017) Eur. J. 
Med. Chem. 137:338-350. 
38. Becke AD (1988) Phys. Rev. A 38:3098-3100. 
39. Becke AD (1993) J. Chem. Phys. 98:5648-5652. 
40. Lee C, Yang W, Parr RG (1988) Phys. Rev. B Condens. 
Matter 37:785-789. 
41. Zhao Y, Truhlar DG (2008) Acc. Chem. Res. 41:157-167. 
42. Zhao Y, Truhlar DG (2008) Ther. Chem. Acc. 120:215-241. 
43. Hirao H, Thellamurege N, Zhang X (2014) Front. Chem. 
2:14. 
44. Kepp KP (2013) Coord. Chem. Rev. 257:196-209. 
45. Verma P, Varga Z, Klein JEMN, Cramer CJ, Que L, Truhlar DG 
(2017) Phys. Chem. Chem. Phys. 19:13049-13069. 
46. Domagal-Goldman SD, Paul KW, Sparks DL, Kubicki JD 
(2009) Geochim Cosmochim Acta. 73:1-12. 
47. Liu Q, Lu X, Li L, Zhang H, Liu G, Zhong H, Zeng H (2016) J. 
Phys. Chem. C 120:21670-21677. 
48. Moreno M, Zacarias A, Porzel A, Velasquez L, Gonzalez G, 
Alegria-Arcos M, Gonzalez-Nilo F, Gross EKU (2018) 
Spectrochim Acta A Mol Biomol Spectrosc 198:264-277. 
49. Kaviani S, Izadyar M, Housaindokht MR (2017) Comput. 
Biol. Chem. 67:114-121. 
50. Matin MA, Chitumalla RK, Lim M, Gao X, Jang J (2015) J. 
Phys. Chem. B 119:5496-5504. 
51. Matin M, Islam M, Bredow T, Aziz M (2017) Adv. Chem. 
Engineer. Sci. 7:137-153. 
52. Bader RFW, Atoms in Molecules, A Quantum Theory, ed. 
O.U. Press. 1994, USA. 
53. Matta CF, Boyd RJ, An Introduction to the Quantum Theory 
of Atoms in Molecules, in The Quantum Theory of Atoms in 
Molecules, C.F.M.a.R.J. Boyd, Editor. 2007. p. 1-34. 
54. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, 
Simmerling C (2006) Proteins 65:712-725. 
55. Giammona DA, PhD thesis. 1984, University of California: 
Davis. 
56. Essmann U, Perera L, Berkowitz ML, Darden TA, Lee H, 
Pedersen LG (1995) J. Chem. Phys. 103:8577-8593. 
57. Liu Y, Liu Y, Drew MGB (2014) Coord. Chem. Rev. 260:37-
64. 
58. Mashiach R, Meijler MM (2013) Org. Lett. 15:1702-1705. 
59. Wang X, Liu C, Zeng X, Wang X, Wang X, Hu Y (2017) Org. 
Lett. 19:3378-3381. 
60. Shanzer A, Libman J, Lifson S, Felder CE (1986) J. Am. Chem. 
Soc. 108:7609-7619. 
61. Boukhalfa H, Crumbliss AL (2002) Biometals 15:325-339. 
62. Raymond KN, Isied SS, Brown LD, Fronczek FR, Nibert JH 
(1976) J. Am. Chem. Soc. 98:1767-1774. 
63. Hay BP, Dixon DA, Vargas R, Garza J, Raymond KN (2001) 
Inorg. Chem. 40:3922-3935. 
64. Dertz EA, Xu J, Stintzi A, Raymond KN (2006) J. Am. Chem. 
Soc. 128:22-23. 
65. Griffin AS, West SA, Buckling A (2004) Nature 430:1024-
1027. 
66. Rapp MV, Maier GP, Dobbs HA, Higdon NJ, Waite JH, Butler 
A, Israelachvili JN (2016) J. Am. Chem. Soc. 138:9013-9016. 
67. Maier GP, Butler A (2017) J. Biol. Inorg. Chem. 22:739-749. 
68. Li Y, Wang T, Xia L, Wang L, Qin M, Li Y, Wang W, Cao Y 
(2017) J. Mater. Chem. B 5:4416-4420. 
69. Ravel J, Cornelis P (2003) Trends Microbiol. 11:195-200. 
70. Lamont IL, Beare PA, Ochsner U, Vasil AI, Vasil ML (2002) 
Proc. Natl. Acad. Sci. USA 99:7072-7077. 
 
